INTRODUCTION: Initial analyses of the novel smokeless tobacco products Camel Snus and Marlboro Snus demonstrated that these products contain relatively low amounts of nicotine and the carcinogenic tobacco-specific nitrosamines N'-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), as compared with traditional smokeless products. It is unknown whether the modifications in packaging, flavors, and pouch sizes that occurred for both Camel Snus and Marlboro Snus since their first introduction to the market were accompanied by any changes in nicotine or nitrosamine levels. METHODS: We examined the available data on nicotine and NNN and NNK levels in 60 samples of Camel Snus and 87 samples of Marlboro Snus that were analyzed in our laboratory between 2006 and 2010. RESULTS: Due to the increase in pouch size, the amounts of total nicotine, unprotonated nicotine, and the sum of NNN and NNK present in the large Camel Snus pouches released in 2010 are 1.9-fold, 2.4-fold, and 3.3-fold higher, respectively, than in the original smaller pouches that entered the market in 2006. Total and unprotonated nicotine content in the current version of Marlboro Snus pouches are 2.1-fold and 1.9-fold higher, respectively, and the sum of NNN and NNK is 1.5-fold lower than in the original version. CONCLUSIONS: We observed an increase in nicotine content in single portions of Camel Snus and Marlboro Snus, and an increase in tobacco-specific N-nitrosamine content in single portions of Camel Snus, due to the increases in pouch size that occurred between 2006 and 2010. This finding stresses the importance of tobacco product regulation and ingredient disclosures.
INTRODUCTION: Initial analyses of the novel smokeless tobacco products Camel Snus and Marlboro Snus demonstrated that these products contain relatively low amounts of nicotine and the carcinogenictobacco-specific nitrosaminesN'-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), as compared with traditional smokeless products. It is unknown whether the modifications in packaging, flavors, and pouch sizes that occurred for both Camel Snus and Marlboro Snus since their first introduction to the market were accompanied by any changes in nicotine or nitrosamine levels. METHODS: We examined the available data on nicotine and NNN and NNK levels in 60 samples of Camel Snus and 87 samples of Marlboro Snus that were analyzed in our laboratory between 2006 and 2010. RESULTS: Due to the increase in pouch size, the amounts of total nicotine, unprotonated nicotine, and the sum of NNN and NNK present in the large Camel Snus pouches released in 2010 are 1.9-fold, 2.4-fold, and 3.3-fold higher, respectively, than in the original smaller pouches that entered the market in 2006. Total and unprotonated nicotine content in the current version of Marlboro Snus pouches are 2.1-fold and 1.9-fold higher, respectively, and the sum of NNN and NNK is 1.5-fold lower than in the original version. CONCLUSIONS: We observed an increase in nicotine content in single portions of Camel Snus and Marlboro Snus, and an increase in tobacco-specific N-nitrosamine content in single portions of Camel Snus, due to the increases in pouch size that occurred between 2006 and 2010. This finding stresses the importance of tobacco product regulation and ingredient disclosures.
Authors: David T Levy; Elizabeth A Mumford; K Michael Cummings; Elizabeth A Gilpin; Gary Giovino; Andrew Hyland; David Sweanor; Kenneth E Warner Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-12 Impact factor: 4.254
Authors: Michael Kotlyar; Louise A Hertsgaard; Bruce R Lindgren; Joni A Jensen; Steven G Carmella; Irina Stepanov; Sharon E Murphy; Stephen S Hecht; Dorothy K Hatsukami Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-11-10 Impact factor: 4.254
Authors: Jian-Min Yuan; Woon-Puay Koh; Sharon E Murphy; Yunhua Fan; Renwei Wang; Steven G Carmella; Shaomei Han; Katie Wickham; Yu-Tang Gao; Mimi C Yu; Stephen S Hecht Journal: Cancer Res Date: 2009-03-24 Impact factor: 12.701
Authors: Andrew C Harris; Laura Tally; Clare E Schmidt; Peter Muelken; Irina Stepanov; Subhrakanti Saha; Rachel Isaksson Vogel; Mark G LeSage Journal: Drug Alcohol Depend Date: 2014-12-23 Impact factor: 4.492
Authors: Jeffrey S Stein; A George Wilson; Mikhail N Koffarnus; Michael C Judd; Warren K Bickel Journal: Psychopharmacology (Berl) Date: 2016-10-11 Impact factor: 4.530
Authors: Lu Fan; Shrilatha Balakrishna; Sairam V Jabba; Pamela E Bonner; Seth R Taylor; Marina R Picciotto; Sven-Eric Jordt Journal: Tob Control Date: 2016-10-03 Impact factor: 7.552
Authors: Silvia Balbo; Sandra James-Yi; Charles S Johnson; Michael G O'Sullivan; Irina Stepanov; Mingyao Wang; Dipankar Bandyopadhyay; Fekadu Kassie; Steven Carmella; Pramod Upadhyaya; Stephen S Hecht Journal: Carcinogenesis Date: 2013-05-13 Impact factor: 4.944
Authors: Micah L Berman; Warren K Bickel; Andrew C Harris; Mark G LeSage; Richard J O'Connor; Irina Stepanov; Peter G Shields; Dorothy K Hatsukami Journal: Nicotine Tob Res Date: 2018-09-25 Impact factor: 4.244
Authors: Jessica L Burris; Matthew J Carpenter; Amy E Wahlquist; K Michael Cummings; Kevin M Gray Journal: Nicotine Tob Res Date: 2013-10-15 Impact factor: 4.244
Authors: Robert E Tyx; Angel J Rivera; Glen A Satten; Lisa M Keong; Peter Kuklenyik; Grace E Lee; Tameka S Lawler; Jacob B Kimbrell; Stephen B Stanfill; Liza Valentin-Blasini; Clifford H Watson Journal: PLoS One Date: 2022-05-04 Impact factor: 3.752